PUBLIC COMPANY
saveBoehringer Ingelheim Corp
updated 4mo ago
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval222 co-mentions · 111 sources
- drugTRIJARDY XR96 co-mentions · 89 sources
- tagSmall Molecule96 co-mentions · 95 sources
- drugSYNJARDY35 co-mentions · 35 sources
- drugempagliflozin26 co-mentions · 26 sources
- drugJARDIANCE26 co-mentions · 26 sources
- drugCYLTEZO24 co-mentions · 12 sources
- drugHUMIRA24 co-mentions · 12 sources
pipeline
27
marketed
20
phase 3
0
catalysts ytd
3
approvals ytd
3
recalls ytd
0
Pipeline(27)
view full pipeline →pipeline depth27 products
20Marketed7Unknown
Marketed
(empagliflozin + linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed(empagliflozin + linagliptin)
Type 2 Diabetes
Marketed(empagliflozin + metformin hydrochloride ER)
Type 2 Diabetes
Marketed(linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed(olodaterol hydrochloride + tiotropium bromide)
Chronic Bronchitis
MarketedCYLTEZO
MarketedCombivent Respimat
Bronchospasm
MarketedLINAGLIPTIN
Type 2 Diabetes
MarketedMicardis HCT
Hypertension
MarketedOfev
Systemic Sclerosis (Scleroderma)
MarketedSYNJARDY
Cardiovascular Risk Factors
MarketedSpiriva
Bronchospasm
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and moreThe U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providersstat · 2d ago
- 3 takeaways from a European obesity scientific meetingEli Lilly impressed with its amylin-Zepbound combination data. Elsewhere, Novo demonstrated continued weight loss following a switch to oral and AbbVie and Boehringer gave glimpses into their conte…biopharma_dive · 3d ago
- BMS reports liver injury events in lung disease program, with key readout nearBristol Myers Squibb will soon release Phase 3 data for admilparant that could make or break Contineum Therapeutics’ rival product. But reports of a death due to liver injury in the pharma’s progra…biospace · 3d ago
- Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—againDespite meeting the primary endpoints in a Phase 3 trial, shares of Zealand Pharma dropped in premarket trading Thursday as the up to 9.8% weight loss reflected inferior loss to that generated by c…biospace · 3d ago
- #EASD26: Boehringer's weight loss candidate trails rivals in diabetes and obesityMILAN — Boehringer Ingelheim’s lead obesity candidate prompted weight loss of up to 9.8% in a late-stage trial in patients with both obesity and type 2 diabetes, according to data presented Thursda…endpoints · 4d ago
- Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary endpoints. Yet, with the readout echoing earlier data that underwhelmed analy…fiercebiotech · 4d ago
- Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior splitPlus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…endpoints · 9d ago
- 9 pharma leaders sound ‘alarm bells’ on biotech’s decline in EuropeFrustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”biopharma_dive · 11d ago
- Boehringer adds $250M to value of Variant pact by expanding into cardiovascular diseaseBoehringer Ingelheim has dived deeper into its collaboration with Variant Bio by expanding the collaboration to cover cardiovascular disease to the tune of $250 million.fiercebiotech · 12d ago
- Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectationsViking Therapeutics’ VK2735 met Truist’s “best-case scenario,” with robust weight loss that was largely maintained when patients transitioned to less frequent dosing. Viking’s stock popped more tha…biospace · 12d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that